Substantive final action
SB2308
House adopts conference committee report RV#4133
Relating to the establishment of a consortium to conduct United States Food and Drug Administration's drug development clinical trials with ibogaine to secure the administration's approval of the medication's use for treatment of opioid use disorder, co-occurring substance use disorder, and any other neurological or mental health conditions for which ibogaine demonstrates efficacy and to the administration of that treatment.
Passed House June 1, 2025⭐ Substantive final action
Yea (134)
Nay (4)
Not Voting (1)
Absent (11)
Republicans (88)
96% yea among members casting a yea or nay vote (80–3).
Democrats (62)
98% yea among members casting a yea or nay vote (54–1).